Patents by Inventor Birgitte Friedrichsen

Birgitte Friedrichsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonistic DR3 Ligands
    Publication number: 20170305994
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 26, 2017
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 9737612
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: August 22, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 9713644
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: July 25, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • LLT-1 antibodies with new functional properties
    Patent number: 9376496
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 28, 2016
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
  • LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES
    Publication number: 20160024215
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 28, 2016
    Inventors: Petrus Johannes Louis SPEE, Peter Andreas Nicolai Reumert WAGTMANN, Stefan ZAHN, Elisabeth D. GALSGAARD, Birgitte FRIEDRICHSEN, Véronique BRAUD
  • LLT-1 antibodies with new functional properties
    Patent number: 9127052
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: September 8, 2015
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20140294853
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Antagonistic DR3 ligands
    Patent number: 8765130
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 1, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Humanized antibodies against human interferon-alpha
    Patent number: 8658771
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: February 25, 2014
    Assignee: Argos Therapeutics, Inc.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen, Jan Fleckner
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20130336984
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 19, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • ANTAGONISTIC DR3 LIGANDS
    Publication number: 20130330360
    Abstract: The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 12, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Albrecht Gruhler, Susanne Nedergaard Grell, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES
    Publication number: 20130164299
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Application
    Filed: June 28, 2011
    Publication date: June 27, 2013
    Applicant: C.N.R.S.
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
  • Humanized Antibodies Against Human Interferon-Alpha
    Publication number: 20130101602
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Application
    Filed: December 19, 2012
    Publication date: April 25, 2013
    Applicant: ARGOS THERAPEUTICS, INC.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized antibodies against human interferon-alpha
    Patent number: 8361463
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: January 29, 2013
    Assignee: Argos Therapeutics, Inc.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized Antibodies Against Human Interferon-Alpha
    Publication number: 20120195888
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Application
    Filed: February 1, 2012
    Publication date: August 2, 2012
    Applicant: NOVO NORDISK A/S
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized antibodies against human interferon-alpha
    Patent number: 8163885
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: April 24, 2012
    Assignee: Argos Therapeutics, Inc.
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen
  • Humanized Antibodies Against Human Interferon-Alpha
    Publication number: 20110213125
    Abstract: The present invention provides humanized anti-human IFN-? monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
    Type: Application
    Filed: May 6, 2009
    Publication date: September 1, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Lars Anders Svensson, Soren Padkjaer, Birgitte Friedrichsen, Berit Olsen Krogh, Inger Lund Pedersen